![]() ![]() On the other hand, renin-angiotensin-aldosterone system blockade does not always normalise insulin sensitivity in type 2 diabetes, and the results of studies with the angiotensin-converting enzyme inhibitor ramipril and the angiotensin II receptor blocker losartan are contradictory. However, conclusive evidence on the effect of renin-angiotensin-aldosterone system blockade on morbidity and mortality is lacking, and although aldosterone excess has been implicated in the pathogenesis of insulin resistance and diabetes, there is no evidence that blocking aldosterone synthesis improves insulin resistance or glucose tolerance. Over the past few years, the renin-angiotensin-aldosterone system and antihypertensive treatment have emerged as possible therapeutic targets. First-line therapy in type 2 diabetes is probably a thiazolidinedione or insulin in combination with metformin. Insulin resistance with resultant hyperinsulinaemia is an important characteristic of all the phenotypes. ![]() Recent results suggest that type 2 diabetes mellitus is a heterogeneous condition with different phenotypes that have a common pathophysiological basis in obesity and the metabolic syndrome. II receptor antagonist or angiotensin-converting enzyme inhibitor treatment in type 2 diabetes. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |